Overview

CD123 Redirected Autologous T Cells for AML

Status:
Terminated

Trial end date:
2016-11-18

Target enrollment:

Participant gender:

Summary

Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myeloid Leukemia (AML) subjects.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of Pennsylvania

Treatments:

Cyclophosphamide